Company intelligence / Profile preview

Imel Biotherapeutics

Waltham, Massachusetts, United Statesimelbiotx.com ↗

Ownership: Private
Development stage: Phase 2

Overview

IMEL Biotherapeutics is developing a proprietary MirC platform that replaces dysfunctional mitochondria in cells with healthy ones. In preclinical studies using animal models of Leigh syndrome and human stem/T cells, the company has demonstrated replacement of up to 90% of dysfunctional mitochondria. The lead program targets immunosenescence with plans for a Phase I trial in solid tumors. Additional work is ongoing in rare pediatric mitochondrial disorders such as Leigh syndrome.

Therapeutic areas: ImmunologyRare Diseases
Modalities: Cell-based therapies
Industry: Biotech

Drug pipeline

1 asset

MirC

Phase 2/3

Indications: Cancer, T cell exhaustion, Age-related immunosenescence

Beyond the preview

Go deeper on Imel Biotherapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Imel Biotherapeutics.

Explore the full profile